

Supporting Information

Probing the Determinants of Porosity in Protein Frameworks:

Co-crystals of Cytochrome *c* and an Octa-anionic Calix[4]arene

Jimi M. Alex,^a Giovanna Brancatelli,^b Stefano Volpi,^c Carmela Bonaccorso,^d Alessandro Casnati,^c Silvano Geremia,^{*,b} Peter B. Crowley^{*,a}

^aSchool of Chemistry, National University of Ireland, University Road, Galway, H91 TK33, Ireland.

^bCentre of Excellence in Biocrystallography, Department of Chemical and Pharmaceutical Sciences, University of Trieste, via L. Giorgieri 1, 34127 Trieste, Italy

^cDipartimento di Scienze Chimiche, della Vita e della Sostenibilità Ambientale, Università degli Studi di Parma, delle Scienze 17/A, 43124 Parma, Italy

^dDipartimento di Scienze Chimiche, Università degli Studi di Catania, viale Andrea Doria 6, 95125, Catania

*Correspondence to:

peter.crowley@nuigalway.ie / +353 91 49 24 80

sgeremia@units.it / +39 040 558 3936

Keywords

assembly, calixarene, molecular glue, protein frameworks, supramolecular scaffolds

Experimental

Sample preparation. **sclx₄mc** was synthesized, as described.¹ Millimolar stock solutions of the ligand were prepared in water at pH 6.0. Unlabelled *Saccharomyces cerevisiae* cytc (C102T) was produced as reported,² and horse heart cytc was from Sigma-Aldrich.

Co-crystallization trials. An Oryx8 Robot (Douglas Instruments) and a sparse matrix screen (JCSG++, Jena Bioscience) were used for co-crystallization of yeast cytc and **sclx₄mc** at 20° C. Protein and calixarene were tested at ratios of 1:1, 1:5 and 1:25. Crystals grew only in 1:1 ratio in condition F2 comprising 3.15 M ammonium sulfate and 0.1 M sodium citrate pH 5.0. Horse cytc and **sclx₄mc** were co-crystallized by the hanging drop vapour diffusion method at 20° C, from 52-62 % PEG 3350 and 0.05 M sodium cacodylate at pH 5.5. Drops were prepared by mixing 1 µL of 1.7 mM protein, 0.5 µL of 17 mM ligand and 1.7 mM gadolinium chloride, with 1 µL of reservoir solution. Crystal growth occurred in 56 % PEG 3350 after 4 days.

X-ray data collection. Crystals of ~100 µm dimension were cryo-protected in the reservoir solution supplemented with 20 % glycerol and cryo-cooled in liquid nitrogen. Diffraction data were collected to 1.7 Å resolution for the yeast cytc – **sclx₄mc** crystal using ϕ scans of 0.1° over 360° with an Eiger X 9M detector (PROXIMA-2A, SOLEIL synchrotron). A dataset extending to 2.5 Å resolution was collected for the horse cytc – **sclx₄mc** crystal using ϕ scans of 0.5° over 100° with a PILATUS detector (XRD1 beamline, Elettra Synchrotron).

X-ray structure determination. The observed reflections were processed with the autoPROC pipeline³ (yeast cytc – **sclx₄mc**) or XDS⁴ (horse cytc – **sclx₄mc**). In both cases the data were scaled using POINTLESS⁵ and AIMLESS⁶. *Xtriage* (PHENIX) analysis of the horse cytc – **sclx₄mc** dataset indicated a perfect merohedral twin and a twin law of h, -k, -l was required for refinement.⁷ The two structures were solved by molecular replacement in PHASER⁸ using 5LYC (yeast cytc) or 1HRC (horse cytc) as the search models. The calixarene coordinates and restraints were generated in JLigand.⁹ Iterative cycles of model building in COOT¹⁰ and refinement were performed with BUSTER¹¹ (yeast cytc – **sclx₄mc**) or REFMAC5¹² (horse cytc – **sclx₄mc**) until no further improvements in the R_{free} or electron density were obtained. The final structures were validated with MolProbity¹³ and deposited in the Protein Data Bank as PDB 6suy (yeast cytc – **sclx₄mc**) and PDB 6suv (horse cytc – **sclx₄mc**).

```

Yeast cytc   AEFKA   1   GSAKKGATLF   10   KTRCLQCHTV   20   EKGGPHKVGP   30
Horse cytc   ----- GDVEKGGKIF   VQKCAQCHTV   EKGGKHKKTGP
              *   **   *           * * * * *   * * * * * * *
              *   * * * * *

Yeast cytc           NLHGIFGRHS   40   GQAEGYSYTD   50   ANIKKNVLWD   60
Horse cytc           NLHGLFGRKT   GQAPGFYTD   ANKNKGITWK
              * * * * * * *   * * * *   * * * *   * *   *   *

Yeast cytc           ENNMSEYLTN   70   PKKYIPGTKM   80   AFGGLKKEKD   90
Horse cytc           EETLMEYLEN   PKKYIPGTKM   IFAGIKKKTE
              *           * * * * *   * * * * * * * * * *   * * * *

Yeast cytc           RNDLITYLKK   100  ATE-
Horse cytc           REDLIAYLKK   ATNE
              *   * * * * * * * * * *   * *

```

Fig. S1 Alignment of the yeast and horse heart cytc primary structures.¹⁴ Conserved residues are highlighted with an asterisk.




Fig. S2 The asymmetric units of (A) yeast cytc – sclx₄mc and (B) horse cytc – sclx₄mc comprising 2 or 8 proteins, respectively. The proteins, calixarenes and sodium ions are shown in grey, green, and white.




Fig. S3 The electrostatic surface potentials showing the cationic (blue) and anionic (red) patches of **(A)** yeast cytc and **(B)** horse cytc (APBS Electrostatics, PyMOL). The conserved residues Lys86 and Lys87, which comprise the binding site in both variants are indicated. Heme edge is shown as spheres




Fig. S4 Superposition of yeast (light grey) and horse cytc (dark grey) highlights the binding of **sclx₄mc** to a similar site on each protein. While Lys87 is encapsulated in horse cytc, it interacts laterally in the yeast cytc case.




Fig. S5 $2F_o - F_c$ electron density maps (contoured at 1.0σ) for the protein – *sclx*₄*mc* interfaces in the (A, B) yeast and (C) horse cytc complexes (See main text Fig. 2).




Fig. S6 Calixarene complexation of yeast cytochrome c. **(A)** The side chain of Lys89 encapsulated by **sclx₄** (PDB 3tyi) and **(B)** **sclx₄mc** interacted with Lys86 by an *exo* CH- π bond and with Lys87 by a weak salt bridge (see also Fig. S4).

Table S1. X-ray data collection, processing and refinement statistics

	Yeast cytc – sclx₄mc	Horse cytc – sclx₄mc
<i>Data Collection</i>		
Light source	SOLEIL, PROXIMA-2A	Elettra, XRD1
Wavelength (Å)	0.97624	1.0000
Space group	<i>P</i> 3 ₂ 21	<i>P</i> 4 ₃
Cell constants	<i>a</i> = <i>b</i> = 102.48 Å <i>c</i> = 180.00 Å $\alpha = \beta = 90^\circ, \gamma = 120^\circ$	<i>a</i> = <i>b</i> = 65.59 Å <i>c</i> = 250.69 Å $\alpha = \beta = \gamma = 90^\circ$
Resolution (Å)	56.00-1.74 (1.77-1.74)	46.38 – 2.50 (2.60-2.50)
# reflections	904004 (42248)	94255 (9021)
# unique reflections	44640 (2207)	34903 (3775)
Multiplicity	20.3 (19.1)	2.7 (2.4)
<i>I</i> / σ (<i>I</i>)	15.7 (2.2)	5.9 (2.6)
Completeness (%)	100 (100)	96.3 (92.6)
<i>R</i> _{pim} ^b (%)	3.4 (44.0)	10.1 (24.3)
CC _{1/2}	99.8 (77.9)	94.3 (73.9)
Solvent content (%)	73	57
<i>Refinement</i>		
<i>R</i> _{work}	0.1665	0.1754
<i>R</i> _{free}	0.1790	0.2365
rmsd bonds (Å)	0.0101	0.0114
rmsd angles (°)	1.0858	3.6120
asymmetric unit composition		
protein	2	8
sclx₄mc	2	8
sodium	2	8
acetate	0	8
cacodylate	0	8
sulfate	5	0
water	280	423
Ave. B-factor (Å ²)	31.19	25.67
Clashscore	1.09	6.40
Ramachandran analysis, ^c % residues in		
favoured regions	98.1	97.9
allowed regions	100	100
PDB code	6suy	6suv

^aValues in parentheses correspond to the highest resolution shell

$$^b R_{\text{pim}} = \frac{\sum_{hkl} \sqrt{(1/n-1) \sum_{i=1}^n |I_i(hkl) - \langle I(hkl) \rangle|}}{\sum_{hkl} \sum_i I_i(hkl)}$$

^cDetermined in MolProbity

References

- 1 A. Casnati, Y. Ting, D. Berti, M. Fabbi, A. Pochini and R. Ungaro, D. Sciotto and G. Lombard, *Tetrahedron*, 1993, **49**, 9815.
- 2 (a) P. B. Crowley, P. Ganji and H. Ibrahim, *ChemBioChem*, 2008, **9**, 1029; (b) R. E. McGovern, H. Fernandes, A. R. Khan, N. P. Power and P. B. Crowley, *Nat. Chem.*, 2012, **4**, 527.
- 3 C. Vonrhein, C. Flensburg, P. Keller, A. Sharff, O. Smart, W. Paciorek, T. Womack and G. Bricogne, *Acta Crystallogr. Sect. D: Biol. Crystallogr.*, 2011, **D67**, 293.
- 4 W. Kabsch, *Acta Crystallogr. Sect. D: Biol. Crystallogr.*, 2010, **D66**, 125.
- 5 P. R. Evans, *Acta Crystallogr. Sect. D: Biol. Crystallogr.*, 2011, **D67**, 282.
- 6 P. R. Evans and G. N. Murshudov, *Acta Crystallogr., Sect. D: Biol. Crystallogr.*, 2013, **D69**, 1204.
- 7 P. D. Adams, P. V. Afonine, G. Bunkóczi, V. B. Chen, I. W. Davis, N. Echols, J. J. Headd, L.-W. Hung, G. J. R. Kapral, W. Grosse-Kunstleve, A. J. McCoy, N. W. Moriarty, R. Oeffner, R. J. Read, D. C. Richardson, J. S. Richardson, T. C. Terwilliger and P. H. Zwart, *Acta Crystallogr. Sect. D: Biol. Crystallogr.*, 2010, **D66**, 213.
- 8 A. J. McCoy, R. W. Grosse-Kunstleve, P. D. Adams, M. D. Winn, L. C. Storoni and R. J. Read, *J. Appl. Crystallogr.*, 2007, **40**, 658.
- 9 E. Potterton, P. Briggs, M. Turkenburg and E. A. Dodson, *Acta Crystallogr. Sect. D: Biol. Crystallogr.*, 2003, **D59**, 1131.
- 10 P. Emsley, B. Lohkamp, W. G. Scott and K. Cowtan, *Acta Crystallogr. Sect. D: Biol. Crystallogr.*, 2010, **D66**, 486.
- 11 O. S. Smart, T. O. Womack, C. Flensburg, P. Keller, W. Paciorek, A. Sharff, C. Vonrhein and G. Bricogne, *Acta Crystallogr. Sect. D: Biol. Crystallogr.*, 2012, **D68**, 368.
- 12 A. A. Vagin, R. A. Steiner, A. A. Lebedev, L. Potterton, S. McNicholas, F. Long and G. N. Murshudov, *Acta Crystallogr. Sect. D: Biol. Crystallogr.*, 2004, **60**, 2184.
- 13 V. B. Chen, W. B. Arendall, J. J. Headd, D. A. Keedy, R. M. Immormino, G. J. Kapral, L. W. Murray, J. S. Richardson and D. C. Richardson, *Acta Crystallogr. Sect. D: Biol. Crystallogr.*, 2010, **D66**, 12.
- 14 F. Madeira, Y. m. Park, J. Lee, N. Buso, T. Gur, N. Madhusoodanan, P. Basutkar, A. R.N. Tivey, S. C. Potter, R. D. Finn and R. Lopez, *Nucleic Acids Res.*, 2019, **47**, 636.